EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 19 / No 4 (Avril 2003) Med Sci (Paris), 19 4 (2003) 443-452 References
Free Access
Issue
Med Sci (Paris)
Volume 19, Number 4, Avril 2003
Page(s) 443 - 452
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2003194443
Published online 15 April 2003
  1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet 1998; 77: 31–7. [Google Scholar]
  2. Steinmann B, Royce PM, Supeti-Furga A. the Elhersdanlos syndrome. In: Royce PM, Steinman B, eds. Connective tissue and its heritable disorders. New York: Wiley-Liss, 1993 : 351–408. [Google Scholar]
  3. Mao JR, Bristow J. The Ehlers-Danlos syndrome: on beyond collagens. J Clin Invest 2001; 107: 1063–9. [Google Scholar]
  4. Fichard A, Kleman JP, Ruggiero F. Another look at collagen V and XI molecules. Matrix Biol 1995; 14: 515–31. [Google Scholar]
  5. Birk DE. Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril assembly. Micron 2001; 32: 223–37. [Google Scholar]
  6. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 1993; 5: 869–76. [Google Scholar]
  7. Nicholls AC, McCarron SM, Narcisi P, Pope FM. Molecular abnormalities of type V collagen in the Ehlers- Danlos syndrome. Am J Hum Genet 1994; 62: 523–8. [Google Scholar]
  8. Michalickova K, Susic M, Willing MC, Wenstrup RJ, Cole WG. Mutations of the α 2(V) chain of type V collagen impair matrix assembly and produce Ehlers-Danlos syndrome type I. Hum Mol Genet 1998; 7: 249–55. [Google Scholar]
  9. Richards AJ, Martin S, Nicholls AC, Harrison JB, Pope FM, Burrows NP. A single base mutation in COL5A2 causes Ehlers- Danlos syndrome type II. J Med Genet 1998; 35: 846–8. [Google Scholar]
  10. Toriello HV, Glover TV, Takahara K, et al. A translocation interrupts the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Nat Genet 1996; 13: 361–5 [Google Scholar]
  11. Wenstrup RJ, Langland GT, Willing MC, D’Souza VN, Cole WG. A splice junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro- α1(V) chains results in gravis form of Ehlers- Danlos syndrome (type I). Hum Mol Genet 1996; 5: 1733–6. [Google Scholar]
  12. Nicholls AC, Oliver JE, McCarron S, Harrison JB, Greenspan DS, Pope FM. An exon skipping mutation of a type V collagen gene (COL5A1) in Ehlers-Danlos syndrome. J Med Genet 1996; 33: 940–6. [Google Scholar]
  13. De Paepe A, Nuytinck L, Hausser I, Anton- Lamprecht I, Naeyaert JM. Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. Am J Hum Genet 1997; 60: 547–54 [Google Scholar]
  14. Burrows NP, Nicholls AC, Richards AJ, et al. A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet 1998; 63: 390–8. [Google Scholar]
  15. Giunta C, Steinmann B. Characterization of 11 new mutations in COL5A1 of individuals with Ehlers- Danlos syndrome type IV: preliminary comparison of RNase cleavage, EMC and DHPLC assays. Hum Mutat 2000; 16: 176–7. [Google Scholar]
  16. Schwarze U, Atkinson M, Hoffman GG, Greenspan DS, Byers PH. Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers- Danlos syndrome (types I and II). Am J Hum Genet 2000; 66: 1757–65. [Google Scholar]
  17. Bouma P, Cabral WA, Cole WG, Marini JC. COL5A1 exon 14 splice acceptor mutation causes a functional null allele, haploinsufficiency of α1(V) and abnormal heterotypic interstitial fibrils in Ehlers-Danlos syndrome II. J Biol Chem 2001; 276: 13356–64. [Google Scholar]
  18. Imamura Y, Scott IC, Greenspan DS. The pro- α3(V) collagen chain. Complete primary structure, expression domains in adult and developing tissues, and comparison to the structures and expression domains of the other types V and XI procollagen chains. J Biol Chem 2000; 275: 8749–59. [Google Scholar]
  19. Chernousov MA, Rothblum K, Tyler WA, Stahl RC, Carey DJ. Schwann cells synthesize type V collagen that contains a novel α4 chain. Molecular cloning, biochemical characterization, and high affinity heparin binding of α4(V) collagen. J Biol Chem 2000; 275: 28208–15. [Google Scholar]
  20. Nuytinck L, Freund M, Lagae L, Pierard GE, Hermanns-Le T, De Paepe A. Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. Am J Hum Genet 2000; 66: 1398–402. [Google Scholar]
  21. Burch GH, Gong Y, Liu W, et al. Tenascin-X deficiency is associated with Ehlers- Danlos syndrome. Nat Genet 1997; 17: 104–8. [Google Scholar]
  22. Schalkwijk J, Zweers MC, Steijlen PM, et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 2001; 345: 1167–75. [Google Scholar]
  23. Lohler J, Timpl R, Jaenisch R. Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death. Cell 1984; 38: 597–607. [Google Scholar]
  24. Chipman SD, Sweet HO, Davisson MT, et al. Defective proa2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci USA 1993; 90: 1705–5. [Google Scholar]
  25. Liu X, Wu H, Byrne M, Krane S, Jaenisch R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci USA 1997; 94: 1852–6. [Google Scholar]
  26. Andrikopoulos K, Liu X, Keene DR, Jaenisch R, Ramirez F. Targeted mutation in the col5a2 gene reveals a regulatory role for type V collagen during matrix assembly. Nat Genet 1995; 9 :31–6. [Google Scholar]
  27. Mao JR, Taylor G, Dean WB, et al. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet 2002; 30: 421–5. [Google Scholar]
  28. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 1998; 141: 1277–86. [Google Scholar]
  29. Svensson L, Aszodi A., Reinholt FP, Fassler R, Heinegard D, Oldberg A. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon J Biol Chem 1999; 274: 9636–47. [Google Scholar]
  30. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997; 136: 729–43. [Google Scholar]
  31. Fushimi H, Kameyama M, Shinkai H. Deficiency of the core proteins of dermatan sulphate proteoglycans in a variant form of Ehlers- Danlos syndrome. J Intern Med 1989; 226: 409–16 [Google Scholar]
  32. Quentin E, Gladen A, Roden L, Kresse H. A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome. Proc Natl Acad Sci USA 1990; 87: 1342–6. [Google Scholar]
  33. Kyriakides TR, Zhu YH, Smith LT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 1998; 140: 419–30. [Google Scholar]
  34. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049–54. [Google Scholar]
  35. Ezura Y, Chakravarti S, Oldberg A, Chervoneva I, Birk DE. Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J Cell Biol 2000; 151: 779–88. [Google Scholar]
  36. Fichard A, Tillet E, Delacoux F, Garrone R, Ruggiero F. Human recombinant α1(V) collagen chain. Homotrimeric assembly and subsequent processing. J Biol Chem 1997; 272: 30083–7. [Google Scholar]
  37. Delacoux F, Fichard A, Geourjon C, Garrone R, Ruggiero F. Molecular features of the collagen V heparin binding site. J Biol Chem 1998; 273: 15069–76. [Google Scholar]
  38. Chanut-Delalande H, Fichard A, Bernocco S, Garrone R, Hulmes DJ, Ruggiero F. Control of heterotypic fibril formation by collagen V is determined by chain stoichiometry. J Biol Chem 2001; 276: 24352–9. [Google Scholar]
  39. Scott JE, Thomlinson AM. The structure of interfibrillar proteoglycan bridges (shape modules) in extracellular matrix of fibrous connective tissues and their stability in various chemical environments. J Anat 1998; 192: 391–405. [Google Scholar]
  40. Mundlos S, Chan D, McGill J, Bateman JF. An α1(II) Gly913 to Cys substitution prevents the matrix incorporation of type II collagen which is replaced with type I and III collagens in cartilage from a patient with hypochondrogenesis. Am J Med Genet 1996; 63: 129–36. [Google Scholar]
  41. Ruggiero F, Comte J, Cabanas C, Garrone R. Structural requirements for α1β1 and α2β1 integrin mediated cell adhesion to collagen V. J Cell Sci 1996; 109: 1865–74. [Google Scholar]
  42. Tillet E, Ruggiero F, Nishiyama A, Stallcup WB. The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J Biol Chem 1997; 272: 10769–76. [Google Scholar]
  43. Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F, Pawson T. Discoidin domain receptor 1 is activated independently of β(1) integrin. J Biol Chem 2000; 275: 5779–84. [Google Scholar]
  44. De Paepe A. The Ehlers- Danlos syndrome: a heritable collagen disorder as cause of bleeding. Thromb Haemost 1996; 75: 379–86. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.